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Summary
Background: Recent experimental studies suggest that currently used anesthetics
have neurotoxic effects on young animals. Clinical studies are increasingly publishing
about the effects of anesthesia on the long‐term outcome, providing contradictory
results. The selective alpha‐2 adrenergic receptor agonist dexmedetomidine has
been suggested as an alternative nontoxic sedative agent.
Aims: The aim of this systematic review was to assess the potential neuroprotective
and neurobehavioral effects of dexmedetomidine in young animals and children.
Methods: Systematic searches separately for preclinical and clinical studies were
performed in Medline Ovid and Embase on February 14, 2018.
Results: The initial search found preclinical (n = 661) and clinical (n = 240) studies.
A total of 20 preclinical studies were included. None of the clinical studies met the
predefined eligibility criteria. Histologic injury by dexmedetomidine was evaluated in
11 studies, and was confirmed in three of these studies (caspase‐3 activation or
apoptosis). Decrease of injury caused by another anesthetic was evaluated in 16
studies and confirmed in 13 of these. Neurobehavioral tests were performed in
seven out of the 20 studies. Of these seven rodent studies, three studies tested the
effects of dexmedetomidine alone on neurobehavioral outcome in animals (younger
than P21). All three studies found no negative effect of dexmedetomidine on the
outcome. In six studies, outcome was evaluated when dexmedetomidine was admin-
istered following another anesthetic. Dexmedetomidine was found to lessen the
negative effects of the anesthetic.
Conclusion: In animals, dexmedetomidine was found not to induce histologic injury
and to show a beneficial effect when administered with another anesthetic. No clini-
cal results on the long‐term effects in children have been identified yet.
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1 | INTRODUCTION
In December 2016, the FDA issued a warning about the use of gen-
eral anesthetics and sedative drugs in young children (0‐3 years of
age) and pregnant women in their third trimester.1 There is conflict-
ing evidence that currently used anesthetics can affect children's
brain development.2–4 Dexmedetomidine, a highly selective alpha‐2
adrenoceptor agonist, is a sedative with analgesic sparing properties.
Therefore, it has been suggested as an alternative nontoxic sedative
drug.5 It is already clinically widely used as a sedative in adults and
increasingly used in pediatric health care for sedation.6 Due to its
sedative, analgesic and anesthetic‐sparing properties, dexmedeto-
midine can be used for anesthesia or procedural sedation. This might
be advantageous in reducing the toxicity of anesthesia and minimiz-
ing concerns about adverse effects on children's brains. Still little is
known, however, about the toxicity and long‐term effects (more than
48 hours after anesthesia) of dexmedetomidine in humans, especially
in children.5,7,8
Therefore, we performed a systematic review to qualitatively
summarize the available information from preclinical studies in young
animals and clinical studies in children on the effects of dexmedeto-
midine on neurotoxicity and neurobehavioral outcome.
2 | MATERIALS AND METHODS
We performed two systematic electronic searches in Embase and
Medline Ovid, one for preclinical and one for clinical studies (Appen-
dices 1 and 2) according to the Preferred Reporting Items for Sys-
tematic Reviews and Meta‐Analyses (PRISMA) statement.9
The last search in these databases was performed on February
14, 2018. Deduplication of the retrieved citations in the two data-
bases was performed in Endnote.10
For preclinical studies, a broad search strategy was used, of which
most important terms were: dexmedetomidine, animals, neurotoxicity,
development, neuroapoptosis (full search strategy see Appendix 1).
Inclusion criteria were: (a) preclinical in vivo study (young animals were
alive when exposed to general anesthesia), (b) use of dexmedetomidine
as general anesthetic, (c) long‐term outcome data reported, and (d)
original article or abstract. All studies in which animals suffered encom-
passing cerebral ischemia were excluded since we aimed to translate
the conclusions of the preclinical studies to the use of dexmedeto-
midine in standard anesthetic care. We included only research on the
effects on neonatal and young animals and excluded the research on
full‐grown animals (rats older than P21, sheep older than gestation
days 147, and monkeys older than gestation days 165).11
In the search strategy for clinical studies, also a broad search
was performed. Of which, most important terms were: dexmedeto-
midine, neurotoxicity, child, development (full search strategy see
Appendix 2). For clinical studies, the following inclusion criteria were
applied: (a) dexmedetomidine was administered in children, (b)
dexmedetomidine was used as a general anesthetic or sedative, (c)
long‐term outcome data of neurotoxicity, and (d) original article or
abstract.
Two investigators (CvH, HE) independently screened the titles
and abstracts of the citations. Those not meeting inclusion criteria
according to both screeners were excluded, whereas those on which
the screeners disagreed were included for full‐text analysis. There-
after, if available, full‐text studies were read independently by the
same two investigators, after which their full‐text selections were
compared and merged. We decided to also include abstracts which
present all required information relevant for this systematic review
because of the limited number of studies and the fast development
of the field of interest. Reviewers resolved discrepancies through
discussion or, if needed, by adjudication from the third (JdG) and
fourth (SH) reviewer. This resulted in the final selection of studies
included in this systematic review.
The primary outcome measure for preclinical studies was the
effect of dexmedetomidine on neuronal cells: neurotoxicity or less-
ening of toxicity caused by another anesthetic agent. This could be
measured in two ways: either histological analysis of neuronal cells
after exposure to dexmedetomidine (alone or with another anes-
thetic) in vivo or neurobehavioral tests after exposure to dexmedeto-
midine.
The primary outcome measure for clinical studies was children's
long‐term neurobehavioral outcome (more than 48 hours after anes-
thesia) after administration of dexmedetomidine.
The risk of bias for each included study was established with the
SYRCLE's risk of bias tool for preclinical studies.12,13 Data of the
preclinical studies were extracted on a data extraction form made by
the authors (CvH, HE), including details of study population (number,
animal species, age), intervention (drugs, dose, route of delivery,
duration of treatment), and outcome (brain region, histological analy-
sis, neurotoxicity, dexmedetomidine decreases toxicity caused by
another anesthetic, neurobehavioral changes).
3 | RESULTS
The search strategy for preclinical studies identified 661 studies
after deduplication.10 The initial screening of titles and abstracts
What is already known
 Currently used anesthetics are suggested to be neurotoxic.
A possible alternative is dexmedetomidine, which is sug-
gested to be a less neurotoxic and even neuroprotective
sedative agent, at least in animal models.
What this article adds
 Administration of dexmedetomidine in anesthetic prac-
tice in preclinical studies show mostly no toxic effects
and a decrease of injury caused by other anesthetics.
The long‐term neurobehavioral outcome following
dexmedetomidine administration in children needs to be
investigated.
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excluded 304 studies; the remaining 357 studies were selected for
full‐text screening, after which all studies in adult animals were
excluded. This resulted in a final selection of 20 preclinical studies
included in the systematic review (Figure 1, Table 1).9
For the clinical search, 240 studies were identified after dedupli-
cation, of which 212 studies were excluded after title and abstract
screening. In total, 28 studies were eligible for full‐text analysis. This
revealed that 25 studies were not original studies and that three
studies were case reports. No study fulfilled the inclusion criteria
and remained for analysis. This resulted in no included studies (Fig-
ure 2).9
The risk of bias analysis showed that allocation concealment
(timing of randomization) was adequate in all studies and that all but
one study were free from selective outcome reporting (Table 1).
Random outcome assessment was reported in none of the 20
studies; blinding for performance (eg, blinding of caregivers and
researchers) was reported in seven studies and blinding for detection
in 10 studies. No study was completely free from risk of bias
(Table 1).
Study characteristics of the 20 included preclinical studies are
reported in Table 2. The sample size ranged from 9 to 102 per study
and from 2 to 25 animals per group (see Table S1, listing all study
characteristics). Studies compared the effect of dexmedetomidine to
that of another anesthetic (n = 15), control (saline) (n = 3), or both
anesthetic and control (n = 2). In five studies, the anesthetics were
administered to the mother during pregnancy and subsequently
studied in the newborn animal. In 15 studies, the anesthetics were
administered to young animals (P7‐P21). Eighteen studies concerned
rats, one study pregnant monkeys, and one study pregnant ewes.
Dexmedetomidine was mostly injected intraperitoneally, intramuscu-
larly, or subcutaneously. In the monkey14 and ewe15 studies, it was
injected intravenously and in one other study intracerebroventricu-
larly.16 It was given as a single or repeated bolus with an interval
varying between 1 hour and 7 days. The total dose of dexmedeto-
midine per animal ranged from 2 to 525 µg/kg. In 17 studies,
dexmedetomidine was administered in combination with another
anesthetic agent, including ketamine (75 mg/kg intraperitoneal or
intravenous infusion at 20 to 50 mg/kg/h for a period of 12
hours),14,17,18 propofol (intraperitoneal 30 mg/kg/d for a period of
7 days to 100 mg/kg and 1.2 mg/kg/min as continuous infusion for
6 hours),19–22 and inhalation anesthetic (isoflurane 0.75%‐2.0%,
sevoflurane 2.5%‐4% up to 6 hours).15,16,22–31
In total, 18 studies published information about histopathological
outcome and seven studies published information about
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F IGURE 1 PRISMA Flowchart selection
of included preclinical studies. This figure
shows an overview of the systematic
search results and selection of the studies
included for this systematic review. It
shows the search found 661 studies, which
we reduced to 20 studies included for the
preclinical part of this systematic review
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neurobehavioral outcome, of which two studies reported only on
neurobehavioral outcome and not on histopathological outcome
(Tables 2–4). The effects of dexmedetomidine have been shown
using immunohistochemistry, terminal deoxynucleotidyl transferase
dUTP nick end labeling (TUNEL), Western blot, silver staining, and
transmission electron microscopy (TEM; Table 3).
3.1 | Effect of dexmedetomidine vs control on
histopathological outcome
The effects of dexmedetomidine alone on caspase‐3 activity were
investigated in eight studies (Tables 2 and 3).14,16,18,19,25,26,29,32
Detection of caspase‐3 enables to identify neurons that are under-
going apoptotic degeneration. Less (or similar to control) caspase‐3
activity suggests less apoptosis14,16,19,25,26,29 and more caspase‐3
activity suggests more apoptosis after exposure to dexmedetomidine
compared to control (Table 3).18,32 Two studies showed no caspase‐
3 activity 6 hours after a single or repeated dose of dexmedeto-
midine varying between 1 and 75 μg/kg.16,26 In contrast, six other
studies did show caspase‐3 activity after a total dose of dexmedeto-
midine ranging from 25 and 250 μg/kg. Of these six studies, four
studies found the same amount of activity as in the control
group14,19,25,29 and two studies found more activity than in the con-
trol group.18,32 Additionally, one study investigated synaptic cleft
width using electromicroscopy; an increase in width was not
shown.30
In total, six studies addressed apoptosis in relation to
dexmedetomidine alone.16–18,25,30,32 In two studies, apoptosis
increased after a total dose dexmedetomidine ranging from 30 to
250 μg/kg18,32 and apoptosis had not significantly increased in four
studies after a total dexmedetomidine dose ranging from 25 to
100 μg/kg (see Table S1, listing all study characteristics).16,17,25,28
TABLE 1 Risk of bias of included studies
Sequence
generation
Baseline
characteristics
Allocation
concealment
adequately
Random
housing
Blinding
(performance)
Random
outcome
assessment
Blinding
detection)
Incomplete
outcome
data
Free from
selective
outcome
reporting
Duan 201417 y ? y y y n ? y y
Goyagi 201623 n ? ? ? ? n ? n ?
Han 201324 y ? y ? ? n ? y ?
Ibrahim 201522 y ? y y y n y y y
Koo 201414 y ? y ? ? n y n y
Lee 201725 y ? y y y n y y y
Li, J 201619 y ? y y n n ? n y
Li,Y 201416 y ? y ? ? n ? n y
Liao 201426 n ? y ? ? n ? n y
Liu 201618 y ? y y y n y n y
Lv 201720 y ? y y n n ? n y
Olutoye 201515 n ? y y n n y n n
Pancaro 201632 y ? y ? y n y n y
Perez 201727 n ? y y n n y y y
Sanders 200929 n ? y ? n n y y y
Sanders 201028 n ? y y n n y y y
Su 201530 n ? y y n n ? n y
Tachibana 201133 y ? y y ? n ? n y
Wang 201621 y ? y y y n y n y
Zeng 201331 y ? y ? ? n ? n y
N: No; Y: Yes; ?: Not reported; Green: Low risk if bias; Red: High risk of bias.
Sequence generation: Was the allocation sequence adequately generated and applied?
Baseline characteristics allocation: Were the groups similar at baseline or were they adjusted for confounders in the analysis?
Concealment adequately: Was the allocation to the different groups adequately concealed during?
Random housing: Were the animals randomly housed during the experiment?
Blinding (performance): Were the caregivers and/or investigators blinded from knowledge which intervention each animal received during the experi-
ment?
Random outcome assessment: Were animals selected at random for outcome assessment?
Blinding (detection): Was the outcome assessor blinded?
Incomplete outcome data: Were incomplete outcome data adequately addressed? Has dropouts been reported?
Free from selective outcome reporting: Are reports of the study free of selective outcome reporting?
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3.2 | Effect of dexmedetomidine versus other
anesthetic on histopathological outcome
In total, 16 studies reported on dexmedetomidine‐induced decrease
of injury caused by another anesthetic (Table 2). The other agent
was isoflurane in eight studies—0.75% in six studies,16,24,26,28,29,31
1.5% in one,30 and 1.5%‐2.0% in one.15 Total dexmedetomidine dose
ranged from 2 to 225 μg/kg. All of these studies show a decrease of
isoflurane‐induced injury after dexmedetomidine. Two studies stud-
ied the effect of dexmedetomidine after sevoflurane administration
for 6 hours at 2.5%.25,27 Of these, one showed a decrease of injury
(total dexmedetomidine dose 3‐150 μg/kg),27 whereas the other did
not (total dexmedetomidine dose 3‐300 μg/kg).25
Four studies studied the decrease of injury by dexmedetomidine
after injury caused by administration of propofol at a total dose
ranging from 4 to 100 mg/kg/d.19–22 Total dexmedetomidine dose
ranged from 3 to 525 μg/kg. Three of the four studies showed a
decrease of injury.19–21 The other study did not show a decrease of
injury caused by dexmedetomidine (3 μg/kg) with co‐administration
of propofol 4 mg/kg or sevoflurane 4.0%.22
Two studies studied the decrease of injury by dexmedetomidine
after injury caused by ketamine administration.17,18 One showed a
decrease of injury (dexmedetomidine dose 75 μg/kg, ketamine dose
75 mg/kg) caused by dexmedetomidine,17 whereas the other study
(dexmedetomidine dose max. 250 μg/kg, ketamine 20 mg/kg/dose)
did not show a decrease of injury.18
3.3 | Effect of dexmedetomidine on
neurobehavioral outcome
In total, seven studies described neurobehavioral testing, all in
rodents (Table 2).17,19,21,23,29,30,33 Three of these studied the effect
of dexmedetomidine only (total dose ranged from 3 to 75 μg/kg) on
fear conditioning, Morris water maze or synaptic plasticity
(Table 4).29,30,33 None reported any functional impairment caused by
dexmedetomidine. Furthermore, in six studies, dexmedetomidine
(dose ranging from 3 to 525 μg/kg) decreased the negative effect on
neurobehavioral outcome caused by coadministration of ketamine,
sevoflurane, propofol, or isoflurane.17,19,21,23,29,30
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4 | DISCUSSION
In a recently published review, dexmedetomidine was proposed as a
suitable alternative for currently used, allegedly toxic anesthetics in
children, and has been suggested to have a neuroprotective effect
when coadministered with these anesthetics.5 In this systematic
review, we analyzed the results of both preclinical and clinical studies
to assess whether dexmedetomidine is a suitable alternative for the
allegedly neurotoxic anesthetic agents. In preclinical studies, exposure
to dexmedetomidine alone had contradictory effects on caspase‐3
activity by histologic examination; no differences with controls in six
studies (total dexmedetomidine dose ranging from 3 to 300 μg/
kg),14,16,19,25,26,29 more caspase‐3 activity in three other studies (total
dexmedetomidine dose ranging from 30 to 250 μg/kg).14,18,32 Coad-
ministration of dexmedetomidine (total dexmedetomidine dose rang-
ing from 3 to 525 μg/kg) decreased the negative histologic effect
caused by other anesthetics in 13 studies15–17,19–21,24,26–31 but the
effect was not found in three other studies.18,22,25 All six studies that
report on adverse neurobehavioral outcome showed a decrease of
injury when coadministration of dexmedetomidine (dose ranging from
3 to 525 μg/kg) with other anesthetics (isoflurane, sevoflurane, keta-
mine, or propofol).17,19,21,23,29,30 To evaluate neuronal injury, most
TABLE 3 Histologic tests
Study Test +protein Result dex alone Result dex +anesthetic
Duan 201417 TUNEL Dex = control Less injury
Han 201324 TUNEL
IHC
WB
No dex alone Less injury
Ibrahim 201522 IHC (caspase‐3)
IMF (caspase‐3)
No dex alone Not less injury
Koo 201414 TUNEL
TEM (activated caspase‐3)
SS
Dex = control
Dex = control
Dex = control
No dex combination
Lee 201725 IHC (caspase‐3)
Microscopy (apoptosis)
Dex = controla
Dex = control
Not less injury
Li 201619 WB (caspase‐3)
IMF (caspase‐3)
Dex = control
Dex = control
Less injury
Li 201416 TUNEL
IHC (caspase‐3)
WB (caspase‐3)
Dex = control
Dex no caspase‐3 activation
Dex = control
Less injury
Liao 201426 TUNEL
WB (caspase‐3)
Dex = control
Dex no caspase‐3 activation
Less injury
Liu 201618 TUNEL (proteinase K)
IHC (caspase‐3)
WB (cleaved caspase‐3)
IMF (caspase‐3)
Dex > control
Dex > control
Dex > control
Dex > control
Not less injury
Lv 201720 TUNEL (proteinase K)
WB (p‐Akt and Akt)
IMF (primary antibody)
TEM
No dex alone Less injury
Olutoye 201515 IHC (anti‐human/mouse caspase‐3) No dex alone Less injury
Pancaro 201632 IHC (rabbit anti‐cleaved caspase‐3)
SS
Dex > control
Dex > control
No dex combination
Perez 201727 Microscope (rabbit anti‐cleaved caspase‐3) No dex alone Less injuryb
Sanders 200929 IHC (rabbit anti‐cleaved caspase‐3) Dex = control Less injury
Sanders 201028 IHC (rabbit anti‐cleaved caspase‐3) No apoptosis Less injury
Su 201530 TEM Dex = control Less injury
Wang 201621 TUNEL
WB (caspase‐3)
No dex alone Less injury
Zeng 201331 TUNEL
WB (?)
No dex alone Less injury
TUNEL; Terminal deoxynucleotidyl transferase dUTP nick end labeling, IHC; immunohistochemistry, WB; Western blot, IMF; immunofluorescence, TEM;
transmission electron microscopy, SS; silver staining, Dex; dexmedetomidine.
aIf dex < 25 μg/kg dex = control. If dex > 25 μg/kg dex > control
bOnly when low‐dose dex was administered in combination with another anesthetic
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studies focused on testing for apoptosis. Other signs of neuronal
injury, such as synaptogenesis and gliogenesis were not used as mark-
ers for neuronal injury by most studies, except for one, which studied
synaptic width to evaluate neuronal injury.30
Furthermore, our systematic search did not yield clinical studies
on children's neurobehavioral outcomes after administration of
dexmedetomidine as a sedative agent. Excluded were studies that
evaluated acute effects after anesthesia (eg, agitation and delirium),
since the aim of this study was to evaluate effects on the long term
(more than 48 hours after anesthesia) only. Although an increase in
publications on dexmedetomidine administration in children for seda-
tion, pain management, and delirium management is noted, studies
focusing on long‐term effects are not published yet.
The reviewed preclinical studies overall show an advantageous
effect of dexmedetomidine regarding neurotoxicity. Histologically,
neurons show less apoptosis after exposure to dexmedetomidine
compared to exposure to other anesthetics (see results).14,16,19,25,26,29
Most of the histologic research focuses on a basic element of toxicity:
apoptosis (and the connected caspase‐3 activity). Apoptosis is pro-
grammed cell death, which can be triggered by cell damage. Cell dam-
age can activate caspase‐3 as a precursor in the pathway that leads to
apoptosis.34 Apoptosis can be marked histologically with techniques
like terminal deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL), silver staining, and Western blot. Using these techniques, a
few study results show brain damage induced by dexmedetomidine;
caspase‐3 activity was increased in animals (Sprague‐Dawley rats)
after exposure to dexmedetomidine.14,18,25,32
Out of the 18 studies that performed histological analysis, 16
addressed decrease of injury caused by another anesthetic agent.
Thirteen of these found a decrease of injury, suggestive of a neuro-
protective effect of dexmedetomidine. Only one study shows major
negative effects of dexmedetomidine coadministered with another
anesthetic. The mortality rate among Wistar rats in that study was
not affected when either sevoflurane 2.5% or dexmedetomidine (5,
25 or 50 μg/kg) was administered alone, but a significant increase in
dose‐dependent mortality and neuronal cell apoptosis was seen
when a total dose of dexmedetomidine ranging from 3 to 150 μg/kg
was co‐administered with 2.5% sevoflurane. In the surviving animals,
however, coadministration of low dose dexmedetomidine (1 and
5 μg/kg) lead to a significant reduction in sevoflurane‐induced
apoptosis.27 Hypothetically, the increased mortality (like suggested
by one study that found increased mortality) might be a sevoflurane
overdose leading to too deep levels of anesthesia resulting in
death.25
Neurobehavioral outcome in animals can be tested by learning
tasks (radial maze), executive tasks (motor skills), memory (eight‐arm
radial maze test), and social skills (fear conditioning). Seven studies
performed neurobehavioral tests, of which the Morris Water Maze
test was used the most.17,21,23,30 This test is used in rodents for
assessing spatial learning and memory. Three of these studies exam-
ined whether administration of dexmedetomidine alone causes
impaired outcome.29,30,33 These studies showed that the outcome of
the tests is worse after exposure to anesthetics compared to control.
Six studies showed that when the rats were subsequently exposed to
dexmedetomidine, performance improved, which indicates that
dexmedetomidine decreases the negative effects caused by other
anesthetics on the neurobehavioral outcome in all tests.17,19,21,23,29,30
Furthermore, overall, studies show that dexmedetomidine itself
does not have a negative effect on task execution and that it amelio-
rates the negative effects caused by other toxic anesthetics.
Anesthetics were mostly injected intraperitoneal, because intra-
venous access is challenging in small animals.35 The total
dexmedetomidine dose administered varied widely between the
included studies, from 3 to 525 μg/kg, in contrast to standard doses
of sevoflurane (2.5%‐4.0%) and isoflurane (0.75%).
The results of the preclinical studies suggest a neuroprotective
profile in animals. However, although there is a logical relation
between experimental and clinical studies, not all pathophysiological
mechanisms can be translated ‘from bench to bed’.36–39 For example,
where sevoflurane is nephrotoxic in preclinical studies, this appears
not to hold for humans.40 On the other hand, interventions that are
harmful in clinical studies may not be harmful in preclinical stud-
ies.41–43 Preclinical studies usually examine toxicity of interventions,
pathology and mechanisms of disease, whereas clinical studies focus
on clinical efficacy.44 Considering these different study objectives,
differences in outcome between preclinical and clinical studies are
not that unexpected. Still, only clinical studies following sufficient
reliable proof from preclinical studies could give an indication of the
safety of new drugs/treatments in humans.45
Furthermore, although an animal data on the large doses of
dexmedetomidine is important and fully within concept of animal
research, it may not be extrapolated to humans: in humans,
dexmedetomidine is used either as a sedative or as an adjunct to
other anesthetics, but never as a “sole anesthetic.”
The present systematic review makes clear that the long‐term
effects of dexmedetomidine in children are not known yet. The mile-
stones of neurobehavioral development vary across species but the
developmental progression in general is comparable. In the first
weeks of life, critical neurodevelopment occurs; apoptosis, synapto-
genesis, gliogenesis, and myelination, regardless of biological differ-
ences between species.46
There are some considerations regarding this review. All studies
in which animals had suffered cerebral ischemia were excluded. Still,
TABLE 4 Neurobehavioral tests
Study
Morris water
maze test Other
Duan 201417 +
Goyagi 201623 +
Li 201619 Eight‐arm radial maze test
Sanders 200929 Fear conditioning
Su 201530 +
Tachibana 201133 Synaptic plasticity
Wang 201621 +
Test performed by study is denoted by ‘+’.
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this is a large group in which dexmedetomidine is suggested to have
a (neuro)protective effect.7,47,48 The results of these studies might
give more information about the effects of dexmedetomidine on the
brain that could help to determine whether dexmedetomidine admin-
istration would be applicable and/or beneficial for secondary preven-
tion after ischemic brain injury. Furthermore, studies that did not
report dexmedetomidine as a general anesthetic agent were
excluded. We aimed to address the effect of dexmedetomidine on
the neurons in the brain, and deemed general anesthesia to be the
best fit to do so. We reasoned that in other applications of anesthe-
sia (such as local anesthesia and nerve block), the drug would possi-
bly not reach the brain.
Importantly, the quality of the studies included in the present
systematic review was intermediate. Not all studies randomly
assigned the animals to the groups, which could have led to con-
founding. Furthermore, methodological descriptions are often poorly
reported. Most important issues are the descriptions of dropouts
and detailed description of the intervention (dose). Only eight out of
20 studies reported on the mortality of the experiment (see
Table S1, listing all study characteristics). When studied animals are
replaced after dropout without description, important outcome can
be missed.
Lastly, we performed a broad search in two databases without
any language limitations or exclusions due to language barriers. Still,
we may have missed relevant studies, with the concomitant risk of
search bias. Furthermore, non‐reporting of study results could have
given rise to publication bias (not reporting certain outcomes) and/or
author bias (judgment of the authors of the study).49
In conclusion, the overall trend of the results shows a substantial
variety in species, exposure paradigm, and histological assessment to
render conclusive results. A clear conclusion cannot be stated: eight
out of 11 studies demonstrated no histological injury by dexmedeto-
midine when administered by itself and 13 out of 16 studies found
beneficial neuroprotective effects of dexmedetomidine coadminis-
trated with other anesthetics.
Dexmedetomidine is currently clinically used, however, as our
systematic search shows, studies are lacking about the long‐term
neurobehavioral effects when administered in children for sedation
or anesthesia. A randomized controlled trial to find out what the
long‐term neurobehavioral effects of dexmedetomidine are in chil-
dren (compared to currently used neurotoxic anesthetics), with the
ultimate aim to find a safe(r) alternative to the currently used neuro-
toxic anesthetics in children is mandatory. Furthermore, the safety
of the combination of dexmedetomidine (especially in high dose)
with other anesthetics needs to be monitored meticulously.
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APPENDIX 1
SEARCH PRECLINICAL STUDIES
Embase
('dexmedetomidine'/exp OR (dexmedetomidine OR cepedex OR dexam-
edetomidine OR dexdomitor OR dexdor OR mpv‐1440 OR mpv1440 OR
precedex OR primadex OR sedadex OR sileo):ab,ti) AND ('neurotoxicity'/
exp OR 'toxicity and intoxication'/de OR intoxication/de OR 'drug intoxi-
cation'/de OR 'neuroprotection'/de OR 'toxicity'/de OR 'brain toxicity'/exp
OR 'drug toxicity'/de OR 'behavior change'/exp OR 'behavior disorder'/exp
OR 'neuropsychology'/de OR 'memory disorder'/de OR 'cognitive defect'/
de OR 'developmental toxicity'/de OR 'nervous system development'/exp
OR 'developmental disorder'/de OR cognition/de OR learning/exp OR
memory/exp OR 'mental capacity'/exp OR 'mental development'/exp OR
'mental performance'/exp OR 'social cognition'/exp OR 'experimental
behavioral test'/exp OR 'neuropsychological test'/exp OR (neurotoxic*
OR neuroprotect*OR toxic*OR intoxicat*OR (behav*NEAR/3 (change*
OR test OR disorder*)) ORmemor*OR neuropsycholog*OR cogniti*OR
learning OR neurocogniti* OR ((development*) NEAR/3 (disorder* OR
dysfunct*OR function*OR declin*OR defect*OR impair*OR improv*))
OR (maze NEAR/3 test*) OR (('nervous system' OR brain) NEAR/3 (de-
velop*)) OR neuroapoptos* OR adhd OR (attention NEAR/3 (deficit OR
hyperactiv*)) OR iq OR intelligence OR autis*):ab,ti) AND ([animals]/lim
OR nonhuman/deOR (rat OR ratsORmouseORmice ORmurine OR ani-
mal*ORmonkey*ORmakak*OR primate*OR nonhuman):ab,ti)
Medline ovid
(Dexmedetomidine/OR (dexmedetomidine OR cepedex OR dexamedeto-
midine OR dexdomitor OR dexdor OR mpv‐1440 OR mpv1440 OR pre-
cedex OR primadex OR sedadex OR sileo).ab,ti.) AND (Neurotoxicity
Syndromes/OR neuroprotection/OR toxicity.xs. OR Memory Disorders/
OR Cognitive Dysfunction/OR nervous system/gd OR Neuropsychology/
OR Developmental Disabilities/OR cognition/OR Cognition Disorders/OR
learning/OR exp memory/OR Neuropsychological Tests/OR (neurotoxic*
OR neuroprotect* OR toxic* OR intoxicat* OR (behav* ADJ3 (change*
OR test OR disorder*)) ORmemor*OR neuropsycholog*OR cogniti*OR
learning OR neurocogniti* OR ((development*) ADJ3 (disorder* OR
dysfunct*OR function*OR declin*OR defect*OR impair*OR improv*))
OR (maze ADJ3 test*) OR ((nervous system OR brain) ADJ3 (develop*))
OR neuroapoptos* OR adhd OR (attention ADJ3 (deificit OR hyperac-
tiv*)) OR iq OR intelligence OR autis*).ab,ti.) AND ((exp animals/NOT
humans/) OR (rat OR rats OR mouse OR mice OR murine OR animal*OR
monkey*ORmakak*OR primate*OR nonhuman).ab,ti.)
APPENDIX 2
SEARCH CLINICAL STUDIES
Embase
('dexmedetomidine'/exp OR (dexmedetomidine OR cepedex OR dex-
amedetomidine OR dexdomitor OR dexdor OR mpv‐1440 OR
mpv1440 OR precedex OR primadex OR sedadex OR sileo):ab,ti) AND
('neurotoxicity'/exp OR 'toxicity and intoxication'/de OR intoxication/
de OR 'drug intoxication'/de OR 'neuroprotection'/de OR 'toxicity'/de
OR 'brain toxicity'/exp OR 'drug toxicity'/de OR 'behavior change'/exp
OR 'behavior disorder'/exp OR 'neuropsychology'/de OR 'memory dis-
order'/de OR 'cognitive defect'/de OR 'developmental toxicity'/de OR
'nervous system development'/exp OR 'developmental disorder'/de OR
cognition/de OR learning/exp OR memory/exp OR 'mental capacity'/
exp OR 'mental development'/exp OR 'mental performance'/exp OR
'social cognition'/exp OR 'experimental behavioral test'/exp OR 'neu-
ropsychological test'/exp OR (neurotoxic* OR neuroprotect* OR tox-
ic* OR intoxicat* OR (behav* NEAR/3 (change* OR test OR
disorder*)) OR memor* OR neuropsycholog* OR cogniti* OR learning
OR neurocogniti* OR ((development*) NEAR/3 (disorder* OR dys-
funct* OR function* OR declin* OR defect* OR impair* OR improv*))
OR (maze NEAR/3 test*) OR (('nervous system' OR brain) NEAR/3 (de-
velop*)) OR neuroapoptos* OR adhd OR (attention NEAR/3 (deficit
OR hyperactiv*)) OR iq OR intelligence OR autis*):ab,ti) AND (child/
exp OR adolescent/exp OR adolescence/exp OR pediatrics/exp OR
childhood/exp OR 'child development'/de OR 'child growth'/de
OR 'child health'/de OR 'child health care'/exp OR 'child care'/exp OR
'childhood disease'/exp OR 'pediatric ward'/de OR 'pediatric hospital'/
de OR (adolescen* OR infan* OR newborn* OR (new NEXT/1 born*)
OR baby OR babies OR neonat* OR child* OR kid OR kids OR tod-
dler* OR teen* OR boy* OR girl* OR minors OR underag* OR (under
NEXT/1 (age* OR aging)) OR juvenil* OR youth* OR kindergar* OR
puber* OR pubescen* OR prepubescen* OR prepubert* OR pediatric*
OR paediatric* OR school* OR preschool* OR highschool*):ab,ti) AND
('anesthesia'/exp OR 'anesthetic agent'/de OR (anesthe* OR anaes-
the*):ab,ti) NOT ([animals]/lim NOT [humans]/lim)
Medline Ovid
(Dexmedetomidine/OR (dexmedetomidine OR cepedex OR dexam-
edetomidine OR dexdomitor OR dexdor OR mpv‐1440 OR mpv1440
OR precedex OR primadex OR sedadex OR sileo).ab,ti.) AND (Neuro-
toxicity Syndromes/OR neuroprotection/OR toxicity.xs. OR Memory
Disorders/OR Cognitive Dysfunction/OR nervous system/gd OR Neu-
ropsychology/OR Developmental Disabilities/OR cognition/OR Cogni-
tion Disorders/OR learning/OR exp memory/OR Neuropsychological
Tests/OR (neurotoxic* OR neuroprotect* OR toxic* OR intoxicat*
OR (behav* ADJ3 (change* OR test OR disorder*)) OR memor* OR
neuropsycholog* OR cogniti* OR learning OR neurocogniti* OR ((de-
velopment*) ADJ3 (disorder* OR dysfunct* OR function* OR declin*
OR defect* OR impair* OR improv*)) OR (maze ADJ3 test*) OR
((nervous system OR brain) ADJ3 (develop*)) OR neuroapoptos* OR
adhd OR (attention ADJ3 (deificit OR hyperactiv*)) OR iq OR intelli-
gence OR autis*).ab,ti.) AND (exp Child/OR exp Infant/OR exp Ado-
lescent/OR exp "Child Behavior"/OR exp "Parent Child Relations"/OR
exp "Pediatrics"/OR "Child Nutrition Sciences"/OR "Infant nutritional
physiological phenomena"/OR exp "Child Welfare"/OR "Child Devel-
opment"/OR exp "Child Health Services"/OR exp "Child Care"/OR
"Child Rearing"/OR exp "Child development Disorders, Pervasive"/
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OR "Child Psychiatry"/OR "Child Psychology"/OR "Hospitals, Pedi-
atric"/OR exp "Intensive Care Units, Pediatric"/OR (adolescen* OR
infan* OR newborn* OR (new ADJ born*) OR baby OR babies OR
neonat* OR child* OR kid OR kids OR toddler* OR teen* OR boy*
OR girl* OR minors OR underag* OR (under ADJ1 (age* OR aging))
OR juvenil* OR youth* OR kindergar* OR puber* OR pubescen* OR
prepubescen* OR prepubert* OR pediatric* OR paediatric* OR
school* OR preschool* OR highschool*).ab,ti.) AND (exp anesthesia/
OR anesthetics/OR (anesthe* OR anaesthe*).ab,ti.) NOT (exp ani-
mals/NOT humans/)
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